Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nitric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.48 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.48 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.48 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1740852 | 0.88 | CYP1A2 (0.67) | CYP1A2HSD17B10SIGMAR1GRIN2DGRIN3B | |
| Nitric Acid SCHEMBL1184113 | 0.83 | CYP1A2 (0.44) | CYP1A2KMT2AMEN1MAPTGAA | |
| Nitric Acid SCHEMBL7231544 | 0.83 | KMT2A (0.53) | CYP1A2SIGMAR1GRIN2DGRIN3BGRIN1 | |
| Nitric Acid SCHEMBL2075832 | 0.83 | KMT2A (0.53) | CYP1A2SIGMAR1GRIN2DGRIN3BGRIN1 | |
| Nitric Acid SCHEMBL2283510 | 0.81 | KMT2A (0.64) | KMT2AMEN1MAPTSMN1; SMN2GAA | |
| Nitric Acid SCHEMBL2862594 | 0.81 | MAPT (0.53) | ALOX5HSD17B10KMT2AMEN1MAPT | |
| Nitric Acid SCHEMBL1363668 | 0.81 | MEN1 (0.50) | KMT2AMEN1MAPTSMN1; SMN2GAA | |
| Nitric Acid SCHEMBL7234512 | 0.81 | MAPT (0.53) | ALOX5HSD17B10KMT2AMEN1MAPT | |
| Nitric Acid SCHEMBL3250036 | 0.81 | MEN1 (0.48) | KMT2AMEN1MAPTSMN1; SMN2GAA | |
| Nitric Acid SCHEMBL27696732 | 0.81 | SIGMAR1 (0.48) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-05-05 | — | — | US | disclosed |
| WO-2009114552-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2009-09-17 | — | — | WO | disclosed |
| EP-0672041-B1 | PHARMACOLOGICALLY ACTIVE PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 2001-11-14 | — | — | EP | disclosed |
| CN-1047776-C | Pharmacologically active pyridine derivatives and processes for the preparation thereof | NOVARTIS AG (CH) | 1999-12-29 | — | — | CN | disclosed |
| US-5728708-A | ANTITUMOR AGENTS | NOVARTIS CORPORATION (US) | 1998-03-17 | — | — | US | disclosed |
| CN-1115982-A | pyridine derivatives having pharmacological activity and preparation method thereof | CIBA GEIGY AG (CH) | 1996-01-31 | — | — | CN | disclosed |
| EP-0672041-A1 | PHARMACOLOGICALLY ACTIVE PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Novartis AG (CH) | 1995-09-20 | — | — | EP | disclosed |
| WO-1995009853-A1 | PHARMACOLOGICALLY ACTIVE PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | CIBA-GEIGY AG (CH) | 1995-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | VHL, TP53, BECN1 | CYP1A2 3844/4885ALOX5 2463/4885HSD17B10 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.